AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea
· Delayed Price · Currency is KRW 8,320.00
+20.00 (0.24%)
Apr 29, 2026, 3:30 PM KST
AptaBio Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -16,346 | -29,378 | -12,062 | -10,565 |
| Depreciation & Amortization | 480.81 | 531.35 | 539.11 | 484.62 |
| Asset Writedown & Restructuring Costs | 475.11 | - | - | - |
| Loss (Gain) From Sale of Investments | -0.28 | 583.55 | 244.29 | 2,494 |
| Loss (Gain) on Equity Investments | 2,653 | 625.93 | 4.19 | - |
| Stock-Based Compensation | 211.51 | 234.34 | 186.65 | 123.6 |
| Provision & Write-off of Bad Debts | 373.63 | - | - | - |
| Other Operating Activities | 455.74 | 12,436 | -2,458 | 631.31 |
| Change in Accounts Receivable | 159.35 | -893.71 | - | - |
| Change in Inventory | 39.54 | -224.87 | - | - |
| Change in Accounts Payable | 31.84 | 1.87 | - | - |
| Change in Other Net Operating Assets | -3,810 | 3,924 | -549.77 | -1.91 |
| Operating Cash Flow | -15,276 | -12,160 | -14,095 | -6,833 |
| Capital Expenditures | -58.67 | -240.16 | -1,345 | -1,041 |
| Sale of Property, Plant & Equipment | 1,400 | - | - | - |
| Cash Acquisitions | 130.49 | - | - | - |
| Sale (Purchase) of Intangibles | - | - | -46.6 | -10.36 |
| Sale (Purchase) of Real Estate | - | - | - | -65.94 |
| Investment in Securities | 6,907 | 13,521 | -9,006 | 5,332 |
| Other Investing Activities | -2,029 | -55.62 | 60.15 | 27.66 |
| Investing Cash Flow | 6,489 | 12,854 | -12,737 | 1,743 |
| Long-Term Debt Issued | - | - | 38,900 | - |
| Long-Term Debt Repaid | -661.25 | -134.01 | -127.85 | -87.95 |
| Net Debt Issued (Repaid) | -661.25 | -134.01 | 38,772 | -87.95 |
| Issuance of Common Stock | - | - | - | 589.2 |
| Other Financing Activities | -17.45 | -33.3 | -19.2 | -5.24 |
| Financing Cash Flow | -678.7 | -167.31 | 49,854 | 496.01 |
| Foreign Exchange Rate Adjustments | 3.28 | -1.19 | 5.07 | 16.76 |
| Miscellaneous Cash Flow Adjustments | 0 | -0 | -0 | 0 |
| Net Cash Flow | -9,463 | 525.33 | 23,027 | -4,577 |
| Free Cash Flow | -15,335 | -12,400 | -15,440 | -7,874 |
| Free Cash Flow Margin | -414.69% | -368.94% | -4767.39% | -16284.04% |
| Free Cash Flow Per Share | -569.45 | -526.76 | -692.42 | -353.27 |
| Cash Interest Paid | 8.43 | 10.2 | 11.47 | 4.49 |
| Cash Income Tax Paid | -152.55 | 76.18 | 48.45 | -34.01 |
| Levered Free Cash Flow | -21,959 | -1,924 | -13,398 | - |
| Unlevered Free Cash Flow | -20,635 | 201.3 | -12,659 | - |
| Change in Working Capital | -3,579 | 2,807 | -549.77 | -1.91 |
Source: S&P Capital IQ. Standard template. Financial Sources.